QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 monopar-announces-mnpr-101-rit-abstract-accepted-as-a-oral-presentation-at-eanm24

Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for c...

 monopar-to-present-data-showcasing-the-appeal-of-upar-as-a-radiopharma-cancer-target-and-of-its-lead-clinical-program-at-the-2024-snmmi-annual-meeting

Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatmen...

 monopars-cfo-kim-r-tsuchimoto-to-retire-june-30-2024-karthik-radhakrishnan-to-succeed-effective-july-1-2024

Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatmen...

 hc-wainwright--co-reiterates-buy-on-monopar-therapeutics-maintains-2-price-target

HC Wainwright & Co. analyst Sean Lee reiterates Monopar Therapeutics (NASDAQ:MNPR) with a Buy and maintains $2 price tar...

 monopar-therapeutics-q1-2024-gaap-eps-010-beats-014-estimate

Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of ...

 monopar-announces-radiopharma-presentation-selected-for-society-of-nuclear-medicine-and-molecular-imaging-2024-annual-meeting

Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments...

 monopar-announces-filing-of-patent-protecting-mnpr-101-radiopharma-optimization-findings

Monopar Therapeutics Inc. (NASDAQ:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments...

 jonestrading-upgrades-monopar-therapeutics-to-buy-announces-2-price-target

JonesTrading analyst Soumit Roy upgrades Monopar Therapeutics (NASDAQ:MNPR) from Hold to Buy and announces $2 price target.

 monopar-therapeutics-q4-gaap-eps-012-beats-015-estimate

Monopar Therapeutics (NASDAQ:MNPR) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of ...

 why-peraso-shares-are-trading-lower-by-over-23-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Peraso Inc. (NASDAQ: PRSO) fell sharply during Tuesday’s session after the company reported worse-than-expected four...